title: Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries.
abstract: OBJECTIVE
  To investigate the impact of clinical risk factors, plasma homocysteine and haemostatic variables on the results after endovascular treatment of symptomatic atherosclerosis of the common iliac artery.
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  The study included 139 technically successful interventions in 103 patients. Technical success was defined as < or = 30% residual stenosis as seen on the post treatment angiogram. Blood samples for analyses of fasting plasma values of homocysteine, fibrinogen, D-dimer, activated protein C resistance were drawn upon admission. Median follow-up for all procedures was 22 months (range 0-55 months). Patency was defined as freedom from > or = 50% restenosis or reocclusion.
  
  
  RESULTS
  The technical success rate for all procedures was 93%. The 1-year cumulative primary patency rate based on intention to treat was 85%. Multivariate analysis revealed a significant independent association between patency rates and levels of fibrinogen and homocysteine and the nature of the lesion treated (stenosis vs. occlusion).
  
  
  CONCLUSIONS
  The aetiology of restenoses and reocclusions is probably multifactorial. Procoagulant activity, the nature of the lesion treated and homocysteine levels within and above the upper range of normal limits are important risk factors for failure after endovascular treatment of the common iliac arteries.
authors.affiliation: Department of Vascular Surgery, Haukeland University Hospital, Bergen, Norway. elin.laxdal@helse-bergen.no
authors.forename: E
authors.initials: E
authors.lastname: Laxdal
authors.forename: J
authors.initials: J
authors.lastname: Wirsching
authors.forename: G
authors.initials: G
authors.lastname: Pedersen
authors.forename: A
authors.initials: A
authors.lastname: Bertz
authors.forename: S R
authors.initials: SR
authors.lastname: Amundsen
authors.forename: E
authors.initials: E
authors.lastname: Dregelid
authors.forename: T
authors.initials: T
authors.lastname: Jonung
authors.forename: T
authors.initials: T
authors.lastname: Nyheim
authors.forename: S
authors.initials: S
authors.lastname: Aune
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon; D050197:Atherosclerosis / Q000628:therapy*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005340:Fibrinogen / Q000032:analysis*; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000453:epidemiology*; D006487:Hemostasis; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007083:Iliac Artery / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome; D014654:Vascular Patency / Q000502:physiology; D014656:Vascular Surgical Procedures
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D006710:Homocysteine; D005340:Fibrinogen